ATLANTA, Feb. 7, 2020 /PRNewswire/ — CorMatrix®Cardiovascular, Inc. www.cormatrix.com, a leading developer of regenerative cardiovascular medical devices, today announced receiving FDA approval to expand and enroll 20 additional patients in the adult arm, including up to 4 additional cardiac surgery research and investigative centers, for […]
Tag: Tricuspid
Rebirth of a Heart Valve: Franciscan Health Surgeon First in World to Use Device
INDIANAPOLIS, Feb. 21, 2019 /PRNewswire/ — A patient who received a first-in-the-world tricuspid valve procedure as part of a new national clinical trial at Franciscan Health Heart Center is home and recovering well. The procedure utilizes a revolutionary material called extracellular matrix. […]
TRiCares Closes €22 Million ($25.4 Million) Series B Financing Round to Fund Development of Minimally Invasive Treatment of Tricuspid Regurgitation
Paris, France and Munich, Germany, June 4, 2018 – TRiCares SAS, a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, is pleased to announce today the successful completion of a €22 Million ($25.4 Million) Series B financing […]
NaviGate Cardiac Structures Inc. (“NCSI”) reports GATE™ bioprosthesis as the first transcatheter valve replacement in Canada to treat tricuspid regurgitation
LAKE FOREST, Calif.–(BUSINESS WIRE)–NaviGate Cardiac Structures Inc. (“NCSI”) announced today that on 2 Feb. 2018, its catheter-guided GATE™ valved-stent bioprosthesis beame the first Canadian orthotopic valve replacement to treat severe tricuspid regurgitation. The procedure was performed at the Quebec Heart and […]
Mitralign Release: SCOUT I Study Using Trialign System for Transcatheter Tricuspid Repair Continues to Show Positive Outcomes at 1 Year
DENVER–(BUSINESS WIRE)– Mitralign, Inc.., an innovative developer of transcatheter tricuspid and mitral valve repair solutions, today released 1 year follow up data from the SCOUT I Early Feasibility Study designed to evaluate the performance of its Trialign™ System. The data presented […]
NaviGate Cardiac Structures, Inc. (“NCSI”) reports first heterotopic transcatheter GATE™ tricuspid valved stent successful implantation
LAKE FOREST, Calif.–(BUSINESS WIRE)–NaviGate Cardiac Structures Inc. (“NCSI”) announced today that the GATE™ catheter-guided tricuspid atrioventricular valved stent (AVS) was implanted through the jugular vein one week ago in a patient suffering from severe tricuspid regurgitation stemming from two failed […]